Teladoc Health’s (TDOC) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of Teladoc Health (NYSE:TDOC) in a report issued on Friday,Weiss Ratings reports.

TDOC has been the subject of a number of other reports. Mizuho initiated coverage on shares of Teladoc Health in a research note on Friday, July 25th. They issued a “neutral” rating and a $10.00 target price for the company. Evercore ISI lifted their target price on shares of Teladoc Health from $8.00 to $9.00 and gave the company an “in-line” rating in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Teladoc Health from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 10th. Finally, Citigroup lifted their target price on shares of Teladoc Health from $9.50 to $10.50 and gave the company a “neutral” rating in a research note on Tuesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $9.97.

Teladoc Health Stock Performance

TDOC stock opened at $9.49 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.58 and a current ratio of 2.67. The stock has a market cap of $1.68 billion, a P/E ratio of -7.97 and a beta of 1.90. The firm has a 50 day simple moving average of $8.11 and a 200 day simple moving average of $7.67. Teladoc Health has a 52 week low of $6.35 and a 52 week high of $15.21.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Tuesday, July 29th. The health services provider reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.08. The business had revenue of $631.90 million during the quarter, compared to analysts’ expectations of $621.91 million. Teladoc Health had a negative net margin of 8.16% and a negative return on equity of 10.13%. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period last year, the company posted ($0.38) earnings per share. Teladoc Health has set its Q3 2025 guidance at -0.350–0.200 EPS. FY 2025 guidance at -1.350–1.000 EPS. Research analysts anticipate that Teladoc Health will post -1.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Teladoc Health

Institutional investors have recently modified their holdings of the company. Golden State Wealth Management LLC raised its position in shares of Teladoc Health by 102.6% in the first quarter. Golden State Wealth Management LLC now owns 3,337 shares of the health services provider’s stock valued at $27,000 after purchasing an additional 1,690 shares during the period. National Bank of Canada FI raised its position in shares of Teladoc Health by 79.4% in the first quarter. National Bank of Canada FI now owns 3,571 shares of the health services provider’s stock valued at $28,000 after purchasing an additional 1,581 shares during the period. SVB Wealth LLC bought a new position in shares of Teladoc Health in the first quarter valued at approximately $37,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Teladoc Health during the first quarter worth $50,000. Finally, Bayforest Capital Ltd bought a new position in Teladoc Health during the third quarter worth $58,000. Institutional investors own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.